RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline

RedHill Biopharma Ltd. Sponsored ADR

RDHL

0.00

RedHill Biopharma highlighted FY 2025 net revenues of USD 7.8 million.
Cash balance was USD 4.1 million, with equity financing capacity of USD 31.7 million.
Talicia, its marketed H. pylori therapy, is co-commercialized in US with Cumberland Pharmaceuticals.
Pipeline focus includes opaganib across oncology and virus-induced ARDS, with an ongoing Phase 2 combination study in prostate cancer with Bayer’s darolutamide.
RHB-102 is positioned for multiple GI indications, with a planned Phase 2 proof-of-concept study for GLP-1/GIP-associated GI intolerance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.